Literature DB >> 12128120

Hypoxia-inducible factor (HIF1A and HIF2A), angiogenesis, and chemoradiotherapy outcome of squamous cell head-and-neck cancer.

Michael I Koukourakis1, Alexandra Giatromanolaki, Efthimios Sivridis, Constantinos Simopoulos, Helen Turley, Kate Talks, Kevin C Gatter, Adrian L Harris.   

Abstract

PURPOSE: Hypoxia-inducible factors HIF1alpha and HIF2alpha (HIFalphas) regulate the expression of a variety of genes encoding proteins related to angiogenesis and to anaerobic metabolism of cells exposed to hypoxic stress. Their putative role as markers of clinically relevant hypoxia and, therefore, as predictors of response to chemoradiotherapy is herein examined. PATIENTS AND METHODS: Using immunohistochemistry, we assessed the expression of HIFalphas in normal head-neck mucosa and in 75 cancer specimens from patients with locally advanced squamous cell head-and-neck cancer (SCHNC), treated with concurrent carboplatin chemoradiotherapy.
RESULTS: Head-and-neck mucosa from normal individuals did not show any HIF1alpha or HIF2alpha reactivity. SCHNC showed a varying expression of HIFalphas ranging through negative reactivity, to weak or focally strong cytoplasmic reactivity, or to strong diffuse cytoplasmic/nuclear reactivity. Fifty-two percent and 33% of cancer samples showed the latter expression pattern for HIF1alpha and HIF2alpha, respectively, and were considered to bear "high" HIF reactivity. Bone/cartilage involvement was more frequent in tumors with high HIF1alpha expression (p = 0.05). HIF1alpha and HIF2alpha overexpression were significantly associated with high microvessel density (p = 0.002 and 0.02, respectively) and with VEGF expression (p = 0.01 and 0.005, respectively). HIF1alpha was related to high thymidine phosphorylase expression (p = 0.03), whereas VEGF/KDR-activated tumor vasculature was significantly more frequent in HIF2alpha-overexpressing tumors (p = 0.02). High HIF1alpha and HIF2alpha were associated with incomplete response to chemoradiation (p = 0.007 and p = 0.02, respectively). In univariate analysis, high HIF1alpha and HIF2alpha expression were significantly associated with poor local relapse-free survival (p = 0.003 and 0.003, respectively) and with poor overall survival (p = 0.05 and 0.001, respectively). In multivariate models, HIF2alpha expression was an independent prognostic factor. In biopsies performed after the delivery of 20 Gy of radiotherapy, upregulation of HIFalphas was noted in some cases.
CONCLUSIONS: It is concluded that the overexpression of HIFalphas in SCHNC is related to locally aggressive behavior, to intensification of angiogenesis, and to an important resistance to carboplatin chemoradiotherapy.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12128120     DOI: 10.1016/s0360-3016(02)02848-1

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  89 in total

1.  Serum signature of hypoxia-regulated factors is associated with progression after induction therapy in head and neck squamous cell cancer.

Authors:  Lauren Averett Byers; F Christopher Holsinger; Merrill S Kies; William N William; Adel K El-Naggar; J Jack Lee; Jianhua Hu; Adriana Lopez; Hai T Tran; Shaoyu Yan; Zhiqiang Du; K Kian Ang; Bonnie S Glisson; Maria Gabriela Raso; Ignacio I Wistuba; Jeffrey N Myers; Waun-Ki Hong; Vali Papadimitrakopoulou; Scott M Lippman; John V Heymach
Journal:  Mol Cancer Ther       Date:  2010-06-08       Impact factor: 6.261

Review 2.  Opportunities and challenges facing biomarker development for personalized head and neck cancer treatment.

Authors:  Alexandra Lucs; Benjamin Saltman; Christine H Chung; Bettie M Steinberg; David L Schwartz
Journal:  Head Neck       Date:  2012-01-27       Impact factor: 3.147

3.  Basal HIF-1α expression levels are not predictive for radiosensitivity of human cancer cell lines.

Authors:  D Schilling; C Bayer; K Emmerich; M Molls; P Vaupel; R M Huber; G Multhoff
Journal:  Strahlenther Onkol       Date:  2012-02-10       Impact factor: 3.621

Review 4.  K+ channel signaling in irradiated tumor cells.

Authors:  Benjamin Stegen; Lukas Klumpp; Milan Misovic; Lena Edalat; Marita Eckert; Dominik Klumpp; Peter Ruth; Stephan M Huber
Journal:  Eur Biophys J       Date:  2016-05-10       Impact factor: 1.733

Review 5.  Molecular responses to hypoxia-inducible factor 1α and beyond.

Authors:  Jason Brocato; Yana Chervona; Max Costa
Journal:  Mol Pharmacol       Date:  2014-02-25       Impact factor: 4.436

Review 6.  Imaging tumor hypoxia to advance radiation oncology.

Authors:  Chen-Ting Lee; Mary-Keara Boss; Mark W Dewhirst
Journal:  Antioxid Redox Signal       Date:  2014-03-24       Impact factor: 8.401

7.  O2-controllable hydrogels for studying cellular responses to hypoxic gradients in three dimensions in vitro and in vivo.

Authors:  Daniel M Lewis; Michael R Blatchley; Kyung Min Park; Sharon Gerecht
Journal:  Nat Protoc       Date:  2017-07-20       Impact factor: 13.491

8.  Overexpression of dimethylarginine dimethylaminohydrolase enhances tumor hypoxia: an insight into the relationship of hypoxia and angiogenesis in vivo.

Authors:  Vassiliki Kostourou; Helen Troy; Joanne F Murray; Elizabeth R Cullis; Guy St J Whitley; John R Griffiths; Simon P Robinson
Journal:  Neoplasia       Date:  2004 Jul-Aug       Impact factor: 5.715

9.  Metabolic Maturation of Human Pluripotent Stem Cell-Derived Cardiomyocytes by Inhibition of HIF1α and LDHA.

Authors:  Dongjian Hu; Annet Linders; Abir Yamak; Cláudia Correia; Jan David Kijlstra; Arman Garakani; Ling Xiao; David J Milan; Peter van der Meer; Margarida Serra; Paula M Alves; Ibrahim J Domian
Journal:  Circ Res       Date:  2018-10-12       Impact factor: 17.367

10.  Beclin-1 expression is a predictor of clinical outcome in patients with esophageal squamous cell carcinoma and correlated to hypoxia-inducible factor (HIF)-1alpha expression.

Authors:  Yongshun Chen; You Lu; Changli Lu; Lei Zhang
Journal:  Pathol Oncol Res       Date:  2009-09       Impact factor: 3.201

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.